You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

shingrix_logo

Product menu

shingrix-unmet-need-banner
Your patients ≥50 years old are at risk for shingles, no matter how healthy they may feel¹⁻⁵*

Age-related decline in immunity is the dominant driver of shingles5-7

shingrix_unmet_need_age

Increasing age causes a natural decline in immunity.5†

shingrix_unmet_need_immunity

There is a reduction in the number and functionality of immune cells that prevents reactivation of VZV.4-8

shingrix_unmet_need_shingles

This leads to an increase in the incidence and severity of
shingles.5-8

Do your patients 50 years and older know they are at risk?

99.5% of people ≥50 years old are at risk for developing shingles.5*

One out of 3 people will get shingles in their lifetime.5*

shingrix_unmet_need_shingles_1
shingrix_unmet_need_shingles_2
shingrix_unmet_need_shingles_3

Do your patients 50 years and older know they are at risk?

shingrix-unmet-need-shingles-1

99.5% of people ≥50 years old are at risk for developing shingles.⁵*

One out of 3 people will get shingles in their lifetime.⁵*

shingrix-unmet-need-shingles-2

Shingles can be painful and can lead to serious, long-lasting complications5:

Postherpetic neuralgia (PHN)

  • Affects up to 30% of patients with shingles9*
  • Characterized by long-lasting nerve pain that can persist for years5

Herpes zoster ophthalmicus

  • Affects up to 25% of patients with shingles5*
  • Can lead to ophthalmic complications and in rare cases, blindness5,10
shingrix-unmet-need-shingles-3
shingrix-unmet-need-box shingrix-unmet-need-box

Learn more about protecting your patients with SHINGRIX▼5-7, 11-15

Video player requires JavaScript enabled. You can download this video here: https://videos.gskinternet.com/pharma/GSKpro/SaudiArabia/MP4/Shingrix/shingrix-video-arabic-scientific-rationale-2-mins-2023.mp4

Discover the cause of shingles and see how SHINGRIX▼ works to directly address it.

*US data. May not be representative of global population.
†Immunocompromise, caused by immunosuppressant drugs or immunodeficient conditions, may also cause immune system decline.
CDC=Centers for Disease Control and Prevention; VZV=varicella zoster virus.

shingrix_icons_efficacy

SHINGRIX▼ protects appropriate patients16

SHINGRIX▼ delivered >90% efficacy against shingles in all age segments ≥50 years old

Learn more

shingrix_icons_people

Meet the patients you can protect5,6,16,17

Nearly everyone ≥50 years old needs shingles protection

Learn more

shingrix_icons_checked

The Saudi Arabia MOH and CDC recommend SHINGRIX▼18-19

Saudi Arabia National Immunization Program recommends HZ vaccine (SHINGRIX▼) 2-doses 2-6 months apart for adults aged ≥ 50 years old for HZ19

The CDC states that SHINGRIX▼ is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years18

Learn more

Shingrix▼ Safety Information16

Contraindications:
Hypersensitivity to the active substances or to any component of the vaccine.

Special warnings and precautions:
As with all injectable vaccines:
- appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine;
- vaccination with Shingrix▼ should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination;
- a protective immune response may not be elicited in all vaccinees.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
There are no data on the use of Shingrix▼ in pregnant women and the effect on breast-fed infants of administration of Shingrix▼ to their mothers has not been studied.

Adverse reactions:
- Very common (≥1/10): headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
- Common (≥1/100 to <1/10): injection site pruritus, malaise.
Please refer to the full prescribing information for further details.

References

  1. Mahalingam R, Wellish M, Wolf W, Dueland AN, Cohrs R, Vafai A, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med. 1990 Sep;323(10):627-31.
  2. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A. 1995 Nov;92(24):10980-84.
  3. Furuta Y, Takasu T, Fukuda S, Sato-Matsumura KC, Inuyama Y, Hondo R, et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis. 1992 Nov;166(5):1157-59.
  4. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, et al. Influence of age and nature of primary infection on varicella-zoster virus—specific cellmediated immune responses. J Infect Dis. 2010;201(7):1024-30.
  5. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008 May;57(RR-5):1-30.
  6. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356(13):1338-43.
  7. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug;24(4):494-500.
  8. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007 Oct;25(41):7087-93.
  9. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun; 4(6):e004833.
  10. Volpi A. Severe complications of herpes zoster. Herpes. 2007 Sep;14 Suppl 2:35-9.
  11. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32(15):1745-53.
  12. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
  13. Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix▼’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug;13(8):1789-97.
  14. Merck Sharp & Dohme. Zostavax European public assessment report, Annex I: Summary of product characteristics: EMA; [updated January 2019; accessed May 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf.
  15. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018 Jun;14(6):1370-7.
  16. Approved prescribing information by SFDA for Shingrix▼.
  17. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-18.
  18. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines.
    MMWR. 2018 Jan;67(3):103-8.
  19. Saudi Arabia Ministry of Health, National Immunization Schedule, 2020, 1-2.

▼This medicine is subjected to additional monitoring. This will allow quick identification of new safety information. You may help by reporting any side effects you may get.

For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia.
Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com

GSK does not recommend, endorse or accept liability for sites controlled by a third party.

Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor
GlaxoSmithKline, Jeddah, 21544, Kingdom of Saudi Arabia.

PM-SA-SGX-WCNT-240011 Date of preparation: March 2025